Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment

  • Kim, Min-Young (Department of Family Practice & Community Health, Ajou University School of Medicine) ;
  • Kim, Kyu-Nam (Department of Family Practice & Community Health, Ajou University School of Medicine) ;
  • Cho, Hye-Min (Department of Family Practice & Community Health, Ajou University School of Medicine) ;
  • Lee, Duck-Joo (Department of Family Practice & Community Health, Ajou University School of Medicine) ;
  • Cho, Doo-Yeoun (Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University)
  • Received : 2016.01.04
  • Accepted : 2016.07.18
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

Amyloid ${\beta}$ ($A{\beta}$) peptides are important components of plaques in patients with Alzheimer's disease (AD). Recent studies suggest that a low plasma ratio of $A{\beta}42$ to $A{\beta}40$ may precede the development of the sporadic form of AD. The aim of this study was to establish reference intervals for plasma $A{\beta}$ in Korean adults. A total of 370 apparently healthy individuals (181 males and 189 females aged 40-69 yr) without cognitive impairment were enrolled. Plasma concentrations of $A{\beta}40$ and $A{\beta}42$ were measured by using a human amyloid ${\beta}$ assay kit (Immuno-Biological Laboratories, Japan). Reference intervals were established according to the "CLSI guidelines for defining, establishing, and verifying reference intervals in the clinical laboratory". There was no need to partition the data with respect to gender or age group. The 95th percentile reference intervals for $A{\beta}40$ and $A{\beta}42$ were 127-331 pg/mL and 2.31-19.84 pg/mL, respectively. The reference interval for the $A{\beta}42/A{\beta}40$ ratio was 0.011-0.092. Plasma $A{\beta}$ concentrations obtained in this study could be used as reference intervals for clinical purposes.

Keywords

Acknowledgement

Supported by : Green Cross Laboratories

References

  1. Knopman DS, Boeve BF, Petersen RC. Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 2003;78:1290-308. https://doi.org/10.4065/78.10.1290
  2. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53. https://doi.org/10.1212/WNL.56.9.1143
  3. Varon D, Loewenstein DA, Potter E, Greig MT, Agron J, Shen Q, et al. Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. Dement Geriatr Cogn Disord 2011;31:276-83. https://doi.org/10.1159/000324711
  4. Gaugler JE, Kane RL, Johnston JA, Sarsour K. Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. Am J Alzheimers Dis Other Demen 2013;28:337-47. https://doi.org/10.1177/1533317513488910
  5. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004;23:105-14. https://doi.org/10.1385/JMN:23:1-2:105
  6. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-9.
  7. Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 2013;5:8. https://doi.org/10.1186/alzrt162
  8. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma $A{\beta}42$/$A{\beta}40$ ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354-62. https://doi.org/10.1001/archneur.64.3.354
  9. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011;305:261-6. https://doi.org/10.1001/jama.2010.1995
  10. Park JH, Park YN, Ko HJ. Modification of the mini-mental state examination for use with the elderly in a non-western society. Part II: cutoff points and their diagnostic validities. Int J Geriat Psychiatry 1991;6:875-82. https://doi.org/10.1002/gps.930061208
  11. Hata S, Fujishige S, Araki Y, Kato N, Araseki M, Nishimura M, et al. Alcadein cleavages by amyloid beta-precursor protein (APP) alpha- and gamma-secretases generate small peptides, p3-Alcs, indicating Alzheimer disease-related gamma-secretase dysfunction. J Biol Chem 2009;284:36024-33. https://doi.org/10.1074/jbc.M109.057497
  12. Ray B, Banerjee PK, Greig NH, Lahiri DK. Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta ($A{\beta}$) peptide in the human neuroblastoma cells. Neurosci Lett 2010;470:1-5. https://doi.org/10.1016/j.neulet.2009.11.016
  13. Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, et al. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline. 3rd ed. EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
  14. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and $A{\beta}42$ in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-81.
  15. Burkhard PR, Fournier R, Mermillod B, Krause KH, Bouras C, Irminger I. Cerebrospinal fluid tau and $A{\beta}42$ concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin Chem Lab Med 2004;42:396-407.
  16. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, et al. $A{\beta}$ peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009;5:18-29. https://doi.org/10.1016/j.jalz.2008.10.004
  17. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, et al. Amyloid-$\beta$ peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000;268:750-6. https://doi.org/10.1006/bbrc.2000.2222
  18. Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, et al. Plasma amyloid-$\beta$ as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 2011;23:399-409. https://doi.org/10.3233/JAD-2010-101335

Cited by

  1. Ethanol Extract of Oldenlandia diffusa Herba Attenuates Scopolamine-Induced Cognitive Impairments in Mice via Activation of BDNF, P-CREB and Inhibition of Acetylcholinesterase vol.19, pp.2, 2016, https://doi.org/10.3390/ijms19020363
  2. Efficacy and Safety of Sesame Oil Cake Extract on Memory Function Improvement: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Pilot Study vol.13, pp.8, 2021, https://doi.org/10.3390/nu13082606